1284243-44-2

Usage

Uses

Used in Pharmaceutical Industry:
TFB-4 is used as a research chemical for the development of new medications, primarily due to its potent and selective serotonin reuptake inhibition properties. Its role in modulating serotonin levels in the brain makes it a candidate for the treatment of mood disorders such as depression and anxiety.
Used in Neuropharmacological Research:
In the field of neuropharmacology, TFB-4 is utilized as a research tool to study the effects of serotonin reuptake inhibition on neural pathways and behavior. Understanding its mechanism of action can contribute to the advancement of treatments for various neurological and psychiatric conditions.
Used in Drug Development for Mood Disorders:
TFB-4 is employed as a lead compound in the development of new drugs targeting mood disorders. Its ability to selectively inhibit serotonin reuptake suggests potential therapeutic benefits for patients suffering from depression and anxiety, warranting further investigation into its safety and efficacy.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 76003-29-7 4-(t-butyloxycarbonyl)piperazin-2-one 
• 460-00-4 1-Bromo-4-fluorobenzene 

Downstream Products

• 780753-89-1 1-(4-fluorophenyl)piperazin-2-one 
• 1284243-45-3 4-{[3-chloro-6-(1H-pyrazol-4-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-(4-fluorophenyl)-2-piperazinone 
• 1284243-40-8 4-{[3-chloro-6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-(4-fluorophenyl)-2-piperazinone 
• 697305-48-9 1-(4-fluorophenyl)piperazin-2-one hydrochloride 

Relevant academic research and scientific papers

Tetrahydroquinazolinone Derivatives as PARP Inhibitors

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

PIPERAZINYL ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).